Lockheed Martin slid this week as the entire defense complex repriced on a single piece of news: a U.S.–Iran peace deal set to be signed in Switzerland. When the war risk that lifted these stocks fades, the premium fades with it — and LMT moved with the group.
By Ruslan Averin.
This is Ruslan Averin's NYSE:LMT stock analysis — a war-premium unwind in a decade-scale franchise.
Why Lockheed fell
Defense names had carried an embedded conflict premium since fighting with Iran broke out. The iShares Aerospace & Defense ETF was down roughly 9% since that fighting began — about 4 percentage points behind the S&P 500 over the same stretch. As the agreement moved toward signing, the logic flipped: peace prices out the war trade, and analysts flagged a likely second leg lower in defense primes. LMT, trading in the $528–$537 range mid-week, slid with them.
| Metric | Value |
|---|---|
| Mid-week range | ~$528–$537 |
| Sector (A&D ETF) | about −9% since fighting began |
| Relative to S&P | about −4 pts |
| F-35 backlog | 416 jets |
| Driver | U.S.–Iran peace deal |
Why I separate the tape from the thesis
Lockheed delivered a record 191 F-35s in 2025 and still holds 416 in backlog, plus expanding Indo-Pacific demand. That order book does not vanish because one conflict ends — it is decade-scale, not headline-scale. So I read this as a repricing of the near-term catalyst, not the franchise. The risk is that a peace narrative keeps a lid on sentiment even while deliveries roll on.
Bottom line
The war premium is leaving, and that is a fair reason for LMT to fall — but the backlog is the part I keep my eye on. The mistake I try to avoid is conflating a faded catalyst with a damaged business: the F-35 program, the Indo-Pacific demand and the multi-year order book are budgeted and contracted well past this week's headline. A peace deal cools sentiment and removes the easy momentum trade, yet it does little to the deliveries that actually drive Lockheed's earnings two and three years out. So I treat this as a re-rating of the story investors tell about LMT, not a re-rating of LMT itself — and those two things eventually reconverge. I do not hold the shares and am not telling anyone to buy or sell — this is analysis, not advice.